IHC of LUAD and LUSQ tissues of a representative case from immune subtypes. The antibodies against CD20 and FOXP3 are used in LUAD (a) and LUSQ tissues (b).
Funding
Japan Agency for Medical Research and Development (AMED)
National Cancer Center Japan (NCC)
MEXT | Japan Society for the Promotion of Science (JSPS)
History
ARTICLE ABSTRACT
The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.